Efficacy and safety of low-dose otelixizumab anti-CD3 monoclonal antibody in preserving C-peptide secretion in adolescent type 1 diabetes: DEFEND-2, a randomized, placebo-controlled, double-blind, multi-centre study

P. Ambery, T. W. Donner, N. Biswas, J. Donaldson, J. Parkin and C. M. Dayan

Diabetic Medicine 31 ( 4 ): 399 - 402 , 2014